Latham & Watkins Advises on Oversubscribed US$150 Million Private Placement in Connection With Werewolf Therapeutics and Ambros Therapeutics’ Reverse Merger Transaction
Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal. The combined company will focus on Ambros' neridronate program for CRPS-1 and trade as AMBX. They secured $150M in private placement from healthcare investors. Latham & Watkins advised on the transaction.
How this was made
The 30-second read
Why it matters
The $150 M raise provides cash for clinical advancement and may improve balance sheets.
Market read
First‑report of a sizable biotech merger and capital raise, creating a new Nasdaq‑listed entity.
What to watch
Regulatory approval risk for neridronate and integration costs may dampen upside.
Background
Latham & Watkins advised the private placement; the merger aims to combine development programs.
Ticker impact
Werewolf Therapeutics announced a definitive all‑stock merger with Ambros Therapeutics and a $150 million oversubscribed private placement.
Short‑term volatility expected; upside if merger synergies are priced in.
The deal creates a new combined entity and injects significant cash, which traders will price in immediately.
Market effects
Consolidation in the pain‑management biotech niche may pressure peers.
Limited to US biotech investors; no broader regional effect.
Minor; primarily affects niche therapeutic sector.
Counterpoint
The merger could overvalue Ambros's pipeline, leading to a post‑deal correction.
Key entities
- Law FirmLatham & Watkins
Advised placement agents on the transaction.
